Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once dai...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Rheum Dis
Main Authors: Keystone, Edward C, Taylor, Peter C, Tanaka, Yoshiya, Gaich, Carol, DeLozier, Amy M, Dudek, Anna, Zamora, Jorge Velasco, Cobos, Jose Arturo Covarrubias, Rooney, Terence, de Bono, Stephanie, Arora, Vipin, Linetzky, Bruno, Weinblatt, Michael E
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2017
Assuntos:
Clinical and Epidemiological Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705852/
https://ncbi.nlm.nih.gov/pubmed/28798049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211259
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares